Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy
Frontiers in Oncology · 14.10.2024 · 14
DOI: 10.3389/fonc.2024.1441935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 14.10.2024. Verfasst von Beiyuan Liang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United States. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
FOLFOX, composed of 5-FU, oxaliplatin and leucovorin, is a first line chemotherapy regimen for colorectal cancer (CRC) treatment. In this study, we show that 5-FU and oxaliplatin induce DNA damage and activate cGAS/STING signaling leading to enhanced expression of interferon (IFN) β, IFN-stimulated genes and inflammatory cytokines in mouse and human colon cancer cells as well as increased intratumoral CD8 + T cells in mice. Crucially, 5-FU and oxaliplatin increase PD-L1 expression at the mRNA and protein levels, which has been shown to inhibit CD8 + T cell function. Depletion of cGAS, STING, IRF3, or IFNα/β receptor 1 (IFNAR1) abolishes this increase, indicating that 5-FU/oxaliplatin mediated upregulation of PD-L1 expression is dependent on tumor cell intrinsic cGAS/STING signaling. These results imply opposing roles for FOLFOX during cancer treatment. On one hand, 5-FU and oxaliplatin activate the innate immune response to facilitate anti-tumor immunity, and conversely upregulate PD-L1 expression to evade immune surveillance. Analysis of TCGA colon cancer dataset shows a positive correlation between expression of PD-L1 and components of the cGAS/STING pathway, supporting a role for cGAS/STING signaling in upregulating PD-L1 expression in colon cancer patients. Tumor studies in syngeneic immune competent mice demonstrate that the combination of 5-FU/oxaliplatin and anti-PD-1 significantly reduced tumor growth of colon cancer cells compared to 5-FU/oxaliplatin treatment alone. Taken together, our studies have identified a unique pathway leading to chemoresistance and provide a rationale to combine FOLFOX with anti-PD-1/PD-L1 as an effective CRC treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United States.
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, United States.
- Pelotonia Institute for Immuno-Oncology, James Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, OH, United States.
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, United States.
Förderung
- NCI NIH HHS
Zitieren
APA
Liang, B., Xing, X., Storts, H., Ye, Z., Claybon, H., Austin, R., Ding, R., Liu, B., Wen, H., Miles, W. O., Fishel, R., & Wang, J. J. (2024). Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1441935
Vancouver
Liang B, Xing X, Storts H, Ye Z, Claybon H, Austin R, et al. Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1441935
BibTeX
@article{Liang2024,
author = {Liang, Beiyuan and Xing, Xuanxuan and Storts, Hayden and Ye, Zhen and Claybon, Hazel and Austin, Ryan and Ding, Rachel and Liu, Bei and Wen, Haitao and Miles, Wayne O and Fishel, Richard and Wang, Jing J},
title = {Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy},
journal = {Frontiers in Oncology},
year = {2024},
volume = {14},
doi = {10.3389/fonc.2024.1441935}
}
EUVIMED